Posted On: 06/01/2015 7:11:46 PM
Post# of 9144
Pros and Cons
Journal Publications
While it's hard to feel good about a ,03 share price, I am trying to stay positive by viewing Michelle's and Gwen's departures as indicators that we're now surely in the sales phase rather than R&D.
What I do find very troubling, however, is the lack of journal pubs on the N-Assay results of almost a year ago. Those pubs are important validations of the technology and we saw pubs like that when the GBS results first came out a few years ago; although, in all honesty those pubs don't seem to have had a dramatic effect on GBS test sales.
I don't understand why academic researchers like the Faros have not published these results. They hold academic, research positions and are expected to publish as well as do doctor-patient work.
Anyone have any thoughts on this? Responses welcome.
Journal Publications
While it's hard to feel good about a ,03 share price, I am trying to stay positive by viewing Michelle's and Gwen's departures as indicators that we're now surely in the sales phase rather than R&D.
What I do find very troubling, however, is the lack of journal pubs on the N-Assay results of almost a year ago. Those pubs are important validations of the technology and we saw pubs like that when the GBS results first came out a few years ago; although, in all honesty those pubs don't seem to have had a dramatic effect on GBS test sales.
I don't understand why academic researchers like the Faros have not published these results. They hold academic, research positions and are expected to publish as well as do doctor-patient work.
Anyone have any thoughts on this? Responses welcome.
(0)
(0)
